TCMs Gain Further U.S. Ground As New Phase III Trial Starts
This article was originally published in PharmAsia News
A Hangzhou-based developer of traditional Chinese medicines (TCMs) has been given the green light by the U.S. Food and Drug Administration to conduct Phase III trials with an injectable TCM-based anticancer drug, which could become the first of its type to enter the U.S. market. The company is also seeking strategic partnerships with big pharmas to advance the trials and for future global development.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.